PT  - JOURNAL ARTICLE
AU  - Pennell, Nathan A.
TI  - Selection of chemotherapy for patients with advanced non–small cell lung cancer
AID  - 10.3949/ccjm.78.s2.10
DP  - 2012 May 01
TA  - Cleveland Clinic Journal of Medicine
PG  - S46--S50
VI  - 79
IP  - 5 e-suppl 1
4099  - http://www.ccjm.org/content/79/5_e-suppl_1/S46.short
4100  - http://www.ccjm.org/content/79/5_e-suppl_1/S46.full
SO  - Cleve Clin J Med2012 May 01; 79
AB  - Chemotherapy remains the first-line treatment for most patients with stage IV non–small cell lung cancer (NSCLC), but optimal regimens are now defined by histology. Platinum-based regimens with pemetrexed, bevacizumab, or both are reasonable first-line options for patients with nonsquamous NSCLC. The standard treatment for squamous NSCLC remains a platinum doublet with a drug other than pemetrexed. Maintenance therapy is emerging as a treatment strategy for patients who do not progress after four cycles of first-line chemotherapy. In the maintenance setting, pemetrexed and erlotinib significantly prolong overall survival compared with placebo after the completion of first-line chemotherapy.